Rescue medication use in patients with chronic obstructive pulmonary disease receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol in England

G. Requena (Brentford, United Kingdom), A. Czira (Brentford, United Kingdom), V. Banks (Bollington, United Kingdom), R. Wood (Bollington, United Kingdom), T. Tritton (Bollington, United Kingdom), C. Castillo (Bollington, United Kingdom), J. Yeap (Bollington, United Kingdom), R. Wild (Bollington, United Kingdom), C. Compton (Brentford, United Kingdom), M. Duarte (Brentford, United Kingdom), K. Rothnie (Brentford, United Kingdom), A. Ismaila (Collegeville, United States)

Source: International Congress 2022 – COPD management: comorbidities, cohorts and real-world studies

Session: COPD management: comorbidities, cohorts and real-world studies
Session type: Thematic Poster
Number: 2118

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Requena (Brentford, United Kingdom), A. Czira (Brentford, United Kingdom), V. Banks (Bollington, United Kingdom), R. Wood (Bollington, United Kingdom), T. Tritton (Bollington, United Kingdom), C. Castillo (Bollington, United Kingdom), J. Yeap (Bollington, United Kingdom), R. Wild (Bollington, United Kingdom), C. Compton (Brentford, United Kingdom), M. Duarte (Brentford, United Kingdom), K. Rothnie (Brentford, United Kingdom), A. Ismaila (Collegeville, United States). Rescue medication use in patients with chronic obstructive pulmonary disease receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol in England. 2118

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.